CBP-501 is under clinical development by CanBas and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CBP-501’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CBP-501 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CBP-501 overview

CBP-501 is under development for the treatment of solid tumor, non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), mesothelioma, head & neck cancer, ovarian cancer, endometrial cancer, breast cancer, bladder cancer, kidney cancer, esophageal cancer, gastric cancer, colon cancer, liver cancer, gallbladder cancer, cholangiocarcinoma, pancreatic cancer, soft tissue sarcoma, and osteosarcoma. The drug candidate is administered through intravenous route as a form of infusion. CBP-501 is a G2 checkpoint inhibitor. It is a peptide with G2 checkpoint-abrogating activity. CBP-501 targets multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1 and CHK2. The drug candidate was also under development for refractory ovarian cancer.

Text-to-speech function is limited to 100 characters Options : History : Help : FeedbackClose

CanBas overview

CanBas, operates as a clinical stage biopharmaceutical company. It develops therapeutics for cancer. The company discovers and develops novel therapeutics in the field of oncology targeting the cell cycle. It provides two clinical oncology programs, CBP501 and CBS9106 with mutually unique MoAs. CanBas product carries out development in CBP501; a modified synthetic peptide enhances the efficacy of cisplatin without adding toxicity. CanBas’ CBP501 is in US Phase II development for first-line treatment of late stage malignant pleural mesothelioma and non-small cell lung cancer. The company’s other drug candidates, CBS9106, an orally-active synthetic small molecule of molecular mass 420, is in the preclinical stage. It also develops techniques to determine the drug-specific sensitivity of individual cancer from a patient. CanBas is headquartered in Numazu, Japan.

Quick View CBP-501 LOA Data

Report Segments
  • Innovator
Drug Name
  • CBP-501
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.